Lantheus (Nasdaq:LNTH) announced that it acquired Cerveau Technologies, a developer of a positron emission tomography imaging agent for detecting Alzheimer’s disease.
Cerveau develops the MK-6240 second-generation F 18-labeled PET imaging agent. It targets Tau tangles in Alzheimer’s disease.
Bedford, Massachusetts–based Lantheus intends to pay an upfront payment and potential development and commercial milestone payments. It also expects to pay double-digit royalty payments for research revenue and commercial sales.
Lantheus structured the deal as a stock purchase. The agreement specifies that, among other things, the seller will provide transition and clinical development services. These will be offered for a prescribed time following the closing of the transaction. Lantheus declined to disclose further terms of the deal.
“This exciting acquisition aligns with our growth strategy, further diversifying our radiopharmaceuti…